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Abstract: Anticoagulant therapy is a major component in the management of acute coronary 
syndromes (ACS). Four anticoagulant agents are currently commercially available for ACS, namely 
unfractionated heparin (UFH), enoxaparin, bivalirudin and fondaparinux. We describe the advan-
tages of fondaparinux and the reasons that have hampered its uptake into routine management 
of ACS. Fondaparinux was shown to be efficacious in the prevention of deep vein thrombosis vs 
low-molecular-weight heparins, while in the setting of venous thrombo-embolic disease, it was 
shown to be noninferior to enoxaparin and UFH. Two pivotal studies have demonstrated the efficacy 
of fondaparinux as an anticoagulant in the setting of ACS, namely OASIS-5 in non-ST elevation 
ACS, and OASIS-6 in ST elevation myocardial infarction (MI). In OASIS-5, fondaparinux was 
shown to be noninferior to enoxaparin in terms of death, MI or refractory ischemia at 9 days. 
Furthermore, a 50% reduction in bleeding complications was obtained with fondaparinux vs 
enoxaparin, leading to a risk reduction for death. In OASIS-6, fondaparinux was shown to be 
superior to the comparator (UFH or placebo). European and North American guidelines give 
fondaparinux a Grade 1A and 1B recommendation respectively, but uptake of fondaparinux in 
routine practice has been slow. We explore reasons for this, such as prevailing doubts about the 
efficacy of fondaparinux in the setting of angioplasty, the problem of catheter thrombosis, and 
the lack of antidote in case of bleeding complications. With the exception of primary angioplasty, 
fondaparinux is as effective as enoxaparin or UFH, but is also associated with a considerable 
reduction in bleeding complications, and thus, an undeniable net clinical benefit.
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Introduction
Anticoagulant therapy is the one of the cornerstones in the management of acute coronary 
syndromes (ACS), in both invasive and noninvasive strategies.1,2 Currently, four anticoagu-
lant agents are commercially available for the treatment of ACS, namely, unfractionated 
heparin (UFH), enoxaparin, bivalirudin, and fondaparinux (pentasaccharide). Each of these 
agents has its different advantages and disadvantages, and there are also differing levels of 
evidence supporting the efficacy and safety of each. In the two years since fondaparinux 
has become commercially available, its place in the management of ACS remains minor, as 
shown by the results of the Euro Heart Survey ACS-3 registry. This article aims to describe 
the advantages of fondaparinux, both theoretical and proven, as well as the reasons why 
its uptake into routine management of ACS has been moderate.
Anticoagulants available in the context of ACS
UFH remains the most frequently used anticoagulant agent in the setting of ACS. It has 
both anti-IIa and anti-Xa effects, and apart from being inexpensive, its further advan-Vascular Health and Risk Management 2010:6 180
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tages are that it is not contra-indicated in case of severe renal 
insufficiency, it has a short half-life, and it can be neutralized 
if necessary using protamine sulfate. The main disadvantage 
of UFH is that its action is neither stable nor predictable, with 
the result that frequent monitoring and dose adjustments are 
necessary, even with intravenous use.
Low-molecular-weight heparins (LMWH), such as 
enoxaparin, have an excellent bioavailability, preferential 
anti-Xa activity, and can be used by intravenous or subcuta-
neous route. They have been shown to be superior to UFH in 
case of “conservative” management strategy3,4 or in the set-
ting of ST elevation myocardial infarction (STEMI) treated 
by thrombolytic therapy.5 In the setting of non-ST elevation 
ACS (NSTE-ACS) submitted to angioplasty, enoxaparin 
has comparable efficacy to UFH, but with more frequent 
hemorrhagic complications6 and has never been tested in 
the setting of primary angioplasty for STEMI.
Bivalirudin represents a third group of anticoagulant 
agents, namely direct thrombin inhibitors. Bivalirudin can be 
administered intravenously, has a predictable efficacy, a very 
short half-life, and no interaction with platelet function. All 
these qualities make bivalirudin an attractive alternative for 
use in the setting of angioplasty. Two large randomized trials 
have compared bivalirudin to a combination of UFH and anti-
GP IIb/IIIa inhibitors, and showed that efficacy was similar, 
with fewer bleeding events under bivalirudin therapy in the 
setting of NSTE-ACS,7 and a reduction in mortality in the 
setting of STEMI treated by primary angioplasty.8
Lastly, fondaparinux is a synthetic pentasaccharide that 
reproduces the sequence in heparins that mediates their inter-
action with antithrombin. It has a pure and selective anti-Xa 
activity through its link with antithrombin. The inhibition of 
thrombin generation is dose-dependent, but without inhibit-
ing the actual thrombin molecule. The mechanism of action 
of fondaparinux is unique, in that the fondaparinux molecule 
attaches itself to the antithrombin, thereby changing its 
structure and allowing the neutralization of factor Xa. After 
inhibition of one factor Xa molecule, the fondaparinux is 
released in its active form by the antithrombin, and can thus 
recirculate and attach to another antithrombin molecule to 
perform another round of inhibition of factor Xa. This cycle 
serves to amplify the effect of fondaparinux. Compared 
to UFH, the affinity of fondaparinux for antithrombin is 
15 times higher, and the inhibition of thrombin generation 
is considerably increased through the anti-Xa activity.9 The 
bioavailability of fondaparinux is 100% after subcutaneous 
injection, and its half-life is around 17 hours. Since it is 
eliminated primarily through the renal route, it is insensitive 
to inactivation by platelet proteins, which neutralise heparin. 
It causes no formation of heparin-PF4 complexes, and does 
not expose the patient to a risk of heparin-induced throm-
bocytopenia.
Studies of fondaparinux  
in the setting of ACS
Fondaparinux was shown to be efficacious in the prevention 
of deep vein thrombosis in the setting of major orthopedic 
surgery compared with usual therapy with LMWH.10,11 In the 
setting of venous thrombo-embolic disease, deep vein throm-
bosis, or pulmonary embolism, fondaparinux was shown 
to be noninferior to enoxaparin and UFH, respectively. On 
the arterial side, the anticoagulant efficacy of fondaparinux 
was demonstrated in a pilot study using primary angioplasty 
as a model of arterial thrombosis.12 Phase II studies were 
carried out in both forms of ACS, namely STEMI13 and 
NSTE-ACS.14 In this latter study, the 2.5 mg once-daily 
dose was shown to have superior efficacy than higher doses 
of fondaparinux and enoxaparin, with a lower rate of bleed-
ing. The 2.5 mg dose was then selected for use in phase III 
randomized trials in ACS with and without ST elevation. 
The two pivotal studies of fondaparinux in this setting were 
OASIS-5,15 which included 20,078 patients with NSTE-ACS, 
and OASIS-6,16 which included 12,092 patients with STEMI. 
In OASIS-5, fondaparinux was shown to be noninferior to 
enoxaparin in terms of the main efficacy endpoints (death, 
MI, refractory ischemia) at 9 days. More importantly, a 
reduction of almost 50% in bleeding complications was 
obtained with fondaparinux compared with enoxaparin 
(2.2% vs 4.1% respectively). This reduction in bleeding had 
a considerable effect on the rate of ischemic events, with a 
significant reduction in death at 30 days and 6 months, but 
also with significant reductions in the combined endpoints 
of death/MI and death/MI/stroke at 30 days and 6 months. 
It is important to underline that this benefit was observed in 
all the predefined subgroups, in particular among the elderly, 
females, patients with renal failure, diabetes patients, and also 
in all risk categories (low, medium, and high risk). Finally, 
and perhaps most important of all, the benefit was consis-
tent in patients submitted to coronary angioplasty, in whom 
fondaparinux was shown to be noninferior at 9 days compared 
with enoxaparin in terms of the main efficacy endpoint, but 
with a considerable reduction in bleeding complications. As 
a result, the net clinical benefit is significantly greater with 
fondaparinux than with enoxaparin.
In the overall population of the OASIS-6 study, 
fondaparinux was shown to be superior to the comparator Vascular Health and Risk Management 2010:6 181
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(UFH or placebo). In OASIS-6, patients were randomized 
to two strata, depending on whether heparin was indicated 
or not (in stratum 1, the comparator was placebo and in 
stratum 2, the comparator was UFH). Not only was a reduc-
tion in mortality or re-infarction observed with fondaparinux 
(7.4% vs 8.9%, P = 0.003 at 9 days, 9.7% vs 11.2%, P = 0.008 
at 30 days and 13.4% vs 14.8%, P = 0.008 at 6 months), 
but there was also a reduction in mortality (6.1% vs 7.0%, 
P = 0.04 at 9 days, 7.8% vs 8.9%, P = 0.03 at 30 days and 
10.5% vs 11.6%, P = 0.03 at 6 months). In parallel, there was 
a trend towards fewer major bleedings, and significantly less 
tamponnade in the fondaparinux group. These results show-
ing a reduced ischemic risk without an increase in bleeding 
risk were observed in patients who were not reperfused, in 
patients submitted to thrombolytic therapy, but not in patients 
treated by primary angioplasty.
The place of fondaparinux  
in European and North American 
guidelines
Since the results of the OASIS-5 and OASIS-6 studies were 
reported, the guidelines for the management of STEMI17 
and NSTE-ACS1,18,19 issued by the ESC, ACC-AHA and 
ACCP have all been updated. Although based on the same 
scientific evidence, the levels of recommendation in the ESC 
and American guidelines are not exactly the same, because 
different criteria were taken into consideration to decide on 
the level of recommendation (Table 1).
In the guidelines issued by the ESC and the ACCP, 
fondaparinux enjoys a grade 1A recommendation in the 
setting of NSTE-ACS, except in case of urgent angioplasty. 
The ACC-AHA guidelines give a grade 1A recommenda-
tion for fondaparinux in case of conservative strategy, but 
grade 1B in case of invasive strategy, and do not make any 
distinction with urgent angioplasty. In the setting of STEMI, 
fondaparinux is recommended over no anticoagulation, in 
patients not undergoing reperfusion, in case of thrombolytic 
therapy, but not in case of primary angioplasty (Figure 1). 
The ACCP recommendations largely follow those of the 
ESC, recommending against the use of fondaparinux in case 
of primary angioplasty. In case of angioplasty in patients 
pretreated with fondaparinux, an additional bolus of 50 to 
100 IU/kg of UFH is recommended.
Finally, the ESC guidelines for the management of 
NSTE-ACS accord particular attention to patients at high 
risk of bleeding, namely women, elderly patients, patients 
with renal failure and those with baseline anemia. The use of 
fondaparinux is recommended in these groups on the basis 
of its superior efficacy–safety profile.
Barriers to the use  
of fondaparinux in ACS
Despite the favorable results of the OASIS-5 and 6 trials 
and the strong recommendations of the European and North 
American guidelines, which give fondaparinux a grade IA or 
IB recommendation in NSTE-ACS, the use of fondaparinux 
in this setting has not been as high as might be expected, par-
ticularly in centers with angioplasty facilities on site. The Euro 
Heart Survey ACS III registry shows that fondaparinux is used 
in only 3% of patients, compared with 43% for UFH and 53% 
for enoxaparin. To date, there has been only one study report-
ing the routine use of fondaparinux in ACS. In a multicenter 
registry of over 2800 patients, the uptake of fondaparinux in 
routine practice 2 years after its first availability on the mar-
ket reportedly depends heavily on local factors. Centers with 
cathlabs on site were reluctant to use fondaparinux routinely, 
preferring UFH or enoxaparin20 (Figure 2). The reasons for 
this choice are manifold, and include prevailing doubts about 
the efficacy of fondaparinux in the setting of angioplasty, the 
problem of catheter thrombosis, and the lack of antidote in 
case of bleeding complications.
Angioplasty under fondaparinux 
therapy
•  The efficacy and safety of fondaparinux in ACS (STEMI 
or NSTE-ACS) has been studied in a pooled analysis of 
the OASIS-5 and 6 data.21 In patients who underwent inva-
sive strategy, fondaparinux reduced mortality at 30 days, 
the combined endpoint (death, MI, or stroke), and major 
bleeding, compared with UFH or enoxaparin.
•  In  NSTE-ACS,  results  from  angioplasty  under 
fondaparinux therapy were studied in the OASIS-5 trial, 
in which 64% of patients underwent invasive diagnostic 
exam during the treatment phase, and 31% (6238) under-
went angioplasty within the first 72 hours. This predefined 
subgroup of patients with invasive strategy was analyzed 
separately.22 In this situation, the benefit obtained with 
fondaparinux compared with enoxaparin was similar to 
that observed in the main cohort, insofar as the rate of 
ischemic events was identical at 9 days, and there was a 
significant reduction in major bleeding (1.6% vs 3.8%, 
hazard ration [HR] 0.42, P  0.001). Furthermore, the 
net clinical benefit was superior with fondaparinux (rate 
of death, infarction, stroke or major bleeding at 9 days of Vascular Health and Risk Management 2010:6 182
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8.2% vs 10.4%, HR = 0.78, P = 0.004) (Table 2). Thus, in 
the context of an early invasive strategy, the results plead 
in favor of fondaparinux. It is noteworthy that the reduc-
tion in bleeding complications appeared very early, with a 
reduction of 35% to 40% from day 1 to day 8 (Table 3).
•  In the setting of STEMI, the results of OASIS-6 are 
also globally in favor of fondaparinux. In stratum II of 
this study (ie, compared to patients treated with UFH), 
the rate of ischemic events was not significantly dif-
ferent between treatment arms. However, in the group 
of patients who underwent primary angioplasty, there 
was a tendency towards an excess of death at 30 days 
(6.1% with fondaparinux vs 5.1% with UFH, P = 0.19) 
(Figure 1 and 3). Although this trend was not significant at 
30 days, and was not observed at all at the other timepoints 
(9 days and 6 months), it could explain why fondaparinux 
is not recommended for use in primary angioplasty in the 
setting of STEMI.17,23 Conversely, in the population of 
2666 patients with STEMI who underwent angioplasty 
other than by primary percutaneous coronary intervention 
(PCI), outcome was favorable under fondaparinux therapy 
compared with UFH (rate of death or infarction of 11.5% 
vs 13.8% respectively, P = 0.08), with a trend towards 
fewer major bleeding events.
The occurrence of catheter 
thrombus
This is a second element that may explain the reluctance of 
certain interventional cardiologists to use fondaparinux in 
angioplasty.
•  Although it was not one of the predefined endpoints, 
the OASIS-5 and -6 investigators reported several 
occurrences of catheter thrombus with fondaparinux. 
This problem had not been encountered during the 
pilot dose-finding study for fondaparinux,14 but in 
OASIS-5, although the rate of coronary occlusion was 
comparable in both arms, the rate of catheter thrombus 
was higher with fondaparinux than with enoxaparin 
(0.9% vs 0.4%, P  0.001). This was confirmed versus 
UFH in OASIS-6 in the setting of primary angioplasty 
Table 1 Classes of recommendations and levels of evidence according to the eSC and ACC/AHA guidelines1,2
Classes of  
recommendations
ESC  ACC/AHA 
Class i evidence and/or general agreement that  
a given treatment or procedure is beneficial,  
useful and effective
Benefit  Risk  
Procedure/treatment should  
be performed
Class ii Conflicting evidence and/or divergence  
of opinion about the usefulness/efficacy  
of a given treatment procedure
–
Class iia weight of evidence/opinion is in favor  
of usefulness/efficacy
Benefit  Risk
Additional studies with focused objectives needed 
It is reasonable to perform procedure/administer 
treatment
Class iib Usefulness/efficacy is less well established  
by evidence/opinion
Benefit  Risk 
Additional studies with broad objectives needed;  
additional registry data would be helpful 
Procedure/treatment may be considered
Class iii evidence or general agreement that the  
given treatment or procedure is not useful/ 
effective and in some cases may be harmful
Risk  evidence 
No additional studies needed 
Procedure/treatment should not be performed/ 
administered since it is not helpful and may be  
harmful
Levels of evidence
A Data derived from multiple randomized  
clinical trials or meta-analyses
Multiple (3–5) population risk strata evaluated  
General consistency of direction and magnitude of effect
B Data derived from a single randomized  
clinical trial or large nonrandomized studies
Limited (2–3) population risk strata evaluated
C  Consensus of opinion of the experts and/or  
small studies, retrospective studies, registries
Very limited (1–2) population risk strata evaluated 
Abbreviations: eSC, european Society of Cardiology;  ACC/AHA, American College of Cardiology/American Heart Association.Vascular Health and Risk Management 2010:6 183
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Characteristic
Time from onset to randomization, h
Stratum
UFH Not indicated
UFH Indicated
5658
No.of
Patients
6434
3008
4300
3290
1460
2867
5436
3789
3345
8746
5980
6106
5958
6134
10304
1787
12092
396 (14.0)
UFH or Placebo
No. (%) of Patients with events
281 (8.7)
141 (9.5)
224 (10.3)
218 (13.3)
92 (12.5)
212 (15.1)
372 (13.6)
287 (16.9)
390 (9.0)
170 (5.6)
507 (16.8)
130 (4.3)
547 (18.0)
609 (11.8)
68 (7.7)
677 (11.2)
93 (4.9)
317 (11.2)
Fondaparinux
Favors
Fondaparinux
Favors UFH
or Placebo
Interaction
P Value
0.10
0.77
0.04
0.87
0.58
0.03
0.82
268 (8.3)
110 (7.2)
203 (9.6)
196 (11.9)
73 (10.1)
178 (12.2)
293 (10.9)
246 (15.0)
339 (7.7)
149 (5.1)
436 (14.1)
136 (4.6)
449 (14.5)
527 (10.3)
58 (6.4)
585 (9.7)
0.5 1.0 2.0
Hazard Ratio
(95% Confidence Interval)
114 (6.0)
Initial Reperfusion Therapy
None
Thrombolytic
Sex
Female
Male
Primary PCI
Age, y
<3
3 to <6
6 to <12
¥12
<62
¥62
GRACE score
Prerandomization UFH
No
Yes
Overall
<112
¥112
Figure 1 Rates of death and myocardial infarction in prespecified subgroups at 30 days in the OASIS-6 trial. Reproduced with permission from Yusuf S, Mehta SR, Chro-
lavicius S, et al. effects of Fondaparinux, on mortality and reinfarction in patients with acute ST-segment elevation mycardial infarction: the OASiS-6 randomized trial. JAMA. 
2006;295(13):1519–1530.16 Copyright © 2006 American Medical Association.
Figure 2 Monthly rate of use of unfractionated heparin, enoxaparin and fondaparinux in the whole population and by type of center (A: University center with cath lab facilities 
on site, B: community centers with cath lab on site, C: community centers without cath lab on site). Reproduced with permission from Schiele F, Meneveau N, Seronde MF, 
et al. Routine use of fondaparinux in acute coronary syndromes: a 2-year multicenter experience. Am Heart J. 2010;159(2):190–198.20 Copyright © 2010 elsevier.
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(0% vs 22%, P  0.001). An amendment to the OASIS-5 
protocol authorized the use of a bolus of UFH at the 
time of angioplasty to prevent the occurrence of catheter 
thrombus. This strategy was applicable in 793 OASIS-5 
patients under fondaparinux, but was actually applied 
in only 75 patients, at a median dose of 50 IU/kg, and 
only one case of catheter thrombus was subsequently 
observed.
•  The mechanism leading to the formation of catheter 
thrombus under fondaparinux therapy is not clearly 
elucidated. It is possible that the thrombus formation is 
facilitated by kallikrein, which can lead to activation of 
factor XIIa. In vitro studies have shown that activation 
of factor XIIa can generate thrombin formation after 
contact with artificial surfaces such as catheters24 and 
that compared with heparin or bivalirudin, fondaparinux 
is less efficacious in preventing catheter thrombosis.25
•  The use of an additional bolus of UFH during angioplasty 
seems to be an effective solution in the case of angioplasty 
under fondaparinux therapy. However, although the asso-
ciation of different anticoagulants during angioplasty was 
reported to be safe in terms of the association of bivaliru-
din and UFH,26 the association of enoxaparin with UFH 
was reportedly associated with an excess of hemorrhagic 
events, death, or MI in the SYNERGY study.27
Confusion between urgent  
and early PCI
In the ESC guidelines for NSTE-ACS, three situations 
are outlined in terms of invasive strategy: elective inva-
sive strategy, early invasive strategy with angioplasty and 
revascularization within 72 hours of admission, and finally, 
the so-called “urgent invasive strategy”, which is the least 
common situation, characterized by the persistence of chest 
pain with ECG changes, hemodynamic instability or severe 
arrhythmias. This situation requires immediate angiography 
and urgent angioplasty (Figure 4). The guidelines stipulate 
that in an urgent invasive strategy, fondaparinux should not 
be used, whereas it is indicated as the anticoagulant of choice 
in the other situations. It is thus likely that some confusion 
exists between “early invasive” and “urgent invasive” strat-
egies, particularly since the ACC-AHA guidelines do not 
distinguish these two clinical situations.28,29
No antidote, but neutralization 
possible?
Although fondaparinux has been shown to be safer than UFH 
and enoxaparin, the fact that it cannot be neutralized remains a 
source of concern, particularly since its half-life is quite long. 
Table 2 Clinical outcomes at day 9 in patients undergoing PCi in OASiS-5
All PCI patients Fondaparinux  
N = 3105
Enoxaparin  
N = 3072
Hazard ratio  
(95% CI)
P value
Death, Mi, stroke, 8.2% 10.4% 0.78 (0.67–0.93) 0.004
major bleeding
Death, Mi, stroke 6.3% 6.2% 1.03 (0.84–1.25) 0.79
Major bleeding 2.4% 5.1% 0.46 (0.35–0.61) 0.001
early PCi  
(24 h after admission)
N = 1414 N = 1420
Death, Mi, stroke, 7.3% 9.5% 0.76 (0.59–0.98) 0.035
major bleeding
Death, Mi, stroke 5.3% 5.4% 0.98 (0.71–1.34) 0.89
Major bleeding 2.3% 4.9% 0.48 (0.31–0.72) 0.001
Adapted from Mehta et al.22
Abbreviations: Mi, myocardial infarction; PCi, percutaneous intervention.
Table 3 Major bleedings in PCi patients according to the day after 
randomization
Days after  
randomization
Fondaparinux  
N = 3105
Enoxaparin  
N = 3072
Relative  
risk
P value 
Same day 0.2 0.5 0.35 0.037
1 0.7 1.7 0.40 0.001
2 1.1 2.8 0.40 0.001
3 1.4 3.6 0.40 0.001
4 1.7 4.0 0.42 0.001
5 1.8 4.3 0.42 0.001
6 2.0 4.7 0.42 0.001
7 2.2 5.0 0.43 0.001
8 2.4 5.0 0.45 0.001
Adapted from Mehta et al.22
Abbreviation: PCi, percutaneous intervention.Vascular Health and Risk Management 2010:6 185
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The use of recombinant factor VIIa to counteract major 
bleeding has been described in other types of coagulation 
disorders.30,31 In patients treated with fondaparinux, the use 
of recombinant factor VIIa (Novo7®) was studied among 16 
healthy volunteers. After injection of 10 mg of fondaparinux, 
normalization of the endogenous thrombin potential was 
obtained 2 to 6 hours after administration of 90 µg/kg of factor 
VIIa, suggesting that there is potential for this formula to be 
used in case of bleeding under fondaparinux.32
Other potential obstacles  
to the use of fondaparinux
The factors that determine the choice of anticoagulant in 
any given situation are manifold, and thus, it is difficult 
No. (%) of Patients
Unfractionated
Heparin Fondaparinux
9 Days
Death or reinfarction
Death or reinfarction
Death or reinfarction
No primary PCI
No primary PCI
Primary PCI
Primary PCI
No primary PCI
Primary PCI
No primary PCI
Primary PCI
No primary PCI
Primary PCI
No primary PCI
Primary PCI
No primary PCI
Primary PCI
No primary PCI
Primary PCI
No primary PCI
Primary PCI
Death
Death
Death
Reinfarction
Reinfarction
Reinfarction
Study end (90–180 days)
30 Days
145 (10.9)
78 (4.1)
0.87 (0.69–1.10) 0.25
0.96
0.46
0.74
0.17
0.03
0.17
0.03
0.04
0.11
0.06
0.62
0.97
0.02
0.90
0.08
0.19
0.29
0.36
0.02
0.36
0.008
0.61
0.03
0.79
0.009
0.95
1.01 (0.74–1.38)
0.94 (0.72–1.22)
1.01 (0.70–1.44)
0.55 (0.34–0.91)
0.96 (0.52–1.77)
0.88 (0.69–1.12)
0.60 (0.39–0.93)
0.77 (0.64–0.93)
1.25 (0.77–2.05)
1.06 (0.84–1.33)
0.79 (0.64–0.97)
1.04 (0.79–1.36)
0.61 (0.43–0.88)
1.01 (0.69–1.48)
1.16 (0.85–1.58)
0.82 (0.66–1.02)
1.20 (0.91–1.57)
113 (8.5) 106 (7.9)
60 (3.2) 60 (3.2)
127 (9.5)
78 (4.2)
24 (1.9)
20 (1.1)
153 (11.5)
115 (6.1)
128 (9.6)
85 (4.5)
33 (2.6)
36 (2.0)
193 (14.9)
150 (8.5)
155 (11.9)
107 (6.1)
47 (4.0)
53 (3.2)
43 (3.4)
21 (1.1)
184 (13.8)
97 (5.1)
145 (10.9)
74 (3.9)
54 (4.3)
29 (1.6)
245 (19.0)
143 (8.2)
195 (15.1)
1.4 (5.9)
75 (6.5)
53 (3.2)
Hazard Ratio
(95% confidence
Interval)
P
Value
P Value for
Interaction
Figure 3 OASiS-6: Results in stratum 2 based on whether patients underwent primary PCi (n = 3768) or not. Reproduced with permission from Yusuf S, Mehta SR, Chro-
lavicius S, et al. effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation mycardial infarction: the OASiS-6 randomized trial. JAMA. 
2006;295(13):1519–1530.16 Copyright © 2006 American Medical Association.
*includes all primary PCis in hospital not only for index myocardial infarction.
Abbrivation: PCi, percutaneous coronary intervention.
to list exhaustively all the reasons why fondaparinux is or 
is not used in patients with NSTE-ACS. Nonetheless, it is 
like that medico-legal and/or economic factors, as well as a 
generalized reluctance to change, are responsible for the slow 
uptake of fondaparinux, to the same extent as the scientific 
reasons. In this context, the main reason why fondaparinux 
is not used in the United States is probably because it is not 
approved for use in ACS by the US Food and Drug Admin-
istration, despite the scientific evidence in its favor provided 
by the OASIS-5 and 6 studies. The increasing use of a radial 
approach for coronary angiography and angioplasty is an 
efficacious method of reducing bleeding risk, that probably 
also minimizes the potential benefit of fondaparinux over 
heparins. Conversely, the low cost and synthetic nature of Vascular Health and Risk Management 2010:6 186
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fondaparinux are characteristics that should plead highly 
in its favor. Indeed, the contamination with chondroitin 
sulphate of tissue extracts used to manufacture heparins, 
brought to light by a series of fatal adverse reactions in 
200833 was allegedly voluntary; underlining once again 
the advantage of synthetic molecules over those fabricated 
using tissue extracts.
Conclusion
Fondaparinux is an anticoagulant that presents particular 
advantages for use in the setting of acute coronary syn-
dromes, and its efficacy and safety have been convincingly 
demonstrated in two randomized trials that included a huge 
number of patients across the spectrum of clinical situations 
represented by ACS. With the exception of primary angio-
plasty, fondaparinux is as effective as enoxaparin or UFH, but 
is also associated with a considerable reduction in bleeding 
complications, and thus, an undeniable net clinical benefit. 
The rate of use of fondaparinux in routine practice is as yet 
poorly documented. On the assumption that reluctance to use 
fondaparinux is unjustified, bearing in mind that European 
and North American guidelines recommend fondaparinux as 
the anticoagulant of choice, particularly when there is a high 
risk of bleeding, and in view of its simplicity of use (single 
dose, one daily injection, no monitoring), fondaparinux could 
become one of, if not the most, widely used anticoagulants 
in ACS. However, there remains the problem of patients with 
renal dysfunction, who present a high risk of both thrombosis 
and bleeding, and thus do not qualify for treatment with any 
of the “new” anticoagulants available.
Disclosure
The author declares no conflicts of interest.
References
  1.  Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 Guide-
lines for the Management of Patients With Unstable Angina/Non-ST-
Elevation Myocardial Infarction-Executive Summary A Report of the 
American College of Cardiology/American Heart Association Task 
Force on Practice Guidelines (Writing Committee to Revise the 2002 
Guidelines for the Management of Patients With Unstable Angina/Non-
ST-Elevation Myocardial Infarction) Developed in Collaboration with 
the American College of Emergency Physicians, the Society for Car-
diovascular Angiography and Interventions, and the Society of Thoracic 
Surgeons Endorsed by the American Association of Cardiovascular and 
Pulmonary Rehabilitation and the Society for Academic Emergency 
Medicine. J Am Coll Cardiol. 2007;50(7):652–726.
  2.  Bassand JP, Hamm CW, Ardissino D, et al. Guidelines for the diagnosis 
and treatment of non-ST-segment elevation acute coronary syndromes. 
Eur Heart J. 2007;28(13):1598–1660.
  3.  Cohen M, Demers C, Gurfinkel EP, et al. A comparison of low-
molecular-weight heparin with unfractionated heparin for unstable 
coronary artery disease. Efficacy and Safety of Subcutaneous Enoxa-
parin in Non-Q-Wave Coronary Events Study Group. N Engl J Med. 
1997;337(7):447–452.
Validation
• Routine clinical chemistry, particularly troponins (on presentation and after 6 to 12 hours) and other
   markers according to working diagnoses (e.g. D-dimers, BNP, NT-proBNP)
• Repeat, preferably continuous ST segment monitoring (when available)
• Echocardiogram, MRI, CT or nuclear imaging for differential diagnoses (e.g. aortic dissection,
   pulmonary embolism)
• Responsivenes to antianginal treatment
Urgent < 120 min Early < 72 hours
• Risk score assessment
• Bleeding risk assessment
1-Refractory angina Elevated troponin levels
Dynamic ST or T wave changes
Diabetes mellitus
Reduced renal function (GFR < 60
ml/min/1.73m2)
Depressed LVEF < 40%
Early post MI angina
PCI within 6 months
Prior CABG
Intermediate to high risk according
to a risk score
Elective
No recurrence of chest pain
No signs of heart failure
No abnormalities in the
initial ECG or a second
ECG (6 to 12 hours)
No elevation of troponins
(arrival and at 6–12 hours)
2-Recurrent angina despite intense
antianginal treatment associated with
ST depression (¥2 mm) or deep
negative T waves.
3-Clinical symptoms of heart failure
or hemodynamic instability
4-Life threatening arrhythmias
(ventricular fibrillation or
ventricular tachycardia)
Figure 4 Management Strategy in NeST-ACS according to the Guidelines of the european Society of Cardiology.Vascular Health and Risk Management 2010:6
Vascular Health and Risk Management
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/vascular-health-and-risk-management-journal
Vascular Health and Risk Management is an international, peer-
reviewed journal of therapeutics and risk management, focusing on 
concise rapid reporting of clinical studies on the processes involved 
in the maintenance of vascular health; the monitoring, prevention and 
treatment of vascular disease and its sequelae; and the involvement of 
metabolic disorders, particularly diabetes. This journal is indexed on 
PubMed Central and MedLine. The manuscript management system 
is completely online and includes a very quick and fair peer-review 
system, which is all easy to use. Visit http://www.dovepress.com/ 
testimonials.php to read real quotes from published authors.
187
Fondaparinux and ACS Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
  4.  Antman EM, McCabe CH, Gurfinkel EP, et al. Enoxaparin prevents 
death and cardiac ischemic events in unstable angina/non-Q-wave myo-
cardial infarction. Results of the thrombolysis in myocardial infarction 
(TIMI) 11B trial. Circulation. 1999;100(15):1593–1601.
  5.  Antman EM, Morrow DA, McCabe CH, et al. Enoxaparin versus 
unfractionated heparin with fibrinolysis for ST-elevation myocardial 
infarction. N Engl J Med. 2006;354(14):1477–1488.
  6.  Ferguson JJ, Califf RM, Antman EM, et al. Enoxaparin vs unfraction-
ated heparin in high-risk patients with non-ST-segment elevation 
acute coronary syndromes managed with an intended early invasive 
strategy: primary results of the SYNERGY randomized trial. JAMA. 
2004;292(1):45–54.
  7.  Stone GW, McLaurin BT, Cox DA, et al. Bivalirudin for patients with acute 
coronary syndromes. N Engl J Med. Nov 23 2006;355(21):2203–2216.
  8.  Stone GW, Witzenbichler B, Guagliumi G, et al. Bivalirudin dur-
ing primary PCI in acute myocardial infarction. N Engl J Med. 
2008;358(21):2218–2230.
  9.  Petitou M, Herault JP, Bernat A, et al. Synthesis of thrombin-inhibiting hep-
arin mimetics without side effects. Nature. 1999;398(6726):417–422.
10.  Bauer KA, Eriksson BI, Lassen MR, Turpie AG. Fondaparinux compared 
with enoxaparin for the prevention of venous thromboembolism after 
elective major knee surgery. N Engl J Med. 2001;345(18):1305–1310.
11.  Eriksson BI, Bauer KA, Lassen MR, Turpie AG. Fondaparinux 
compared with enoxaparin for the prevention of venous thromboem-
bolism after hip-fracture surgery. N Engl J Med. 2001 Nov 1;345(18): 
1298–1304.
12.  Vuillemenot A, Schiele F, Meneveau N, et al. Efficacy of a synthetic 
pentasaccharide, a pure factor Xa inhibitor, as an antithrombotic agent–a 
pilot study in the setting of coronary angioplasty. Thromb Haemost. 
1999;81(2):214–220.
13.  Coussement PK, Bassand JP, Convens C, et al. A synthetic factor-
Xa inhibitor (ORG31540/SR9017A) as an adjunct to fibrinolysis in 
acute myocardial infarction. The PENTALYSE study. Eur Heart J. 
2001;22(18):1716–1724.
14.  Mehta SR, Steg PG, Granger CB, et al. Randomized, blinded trial 
comparing fondaparinux with unfractionated heparin in patients 
undergoing contemporary percutaneous coronary intervention: Arixtra 
Study in Percutaneous Coronary Intervention: a Randomized Evaluation 
(ASPIRE) Pilot Trial. Circulation. 2005;111(11):1390–1397.
15.  Yusuf S, Mehta SR, Chrolavicius S, et al. Comparison of fondaparinux 
and enoxaparin in acute coronary syndromes. N Engl J Med. 
2006;354(14):1464–1476.
16.  Yusuf S, Mehta SR, Chrolavicius S, et al. Effects of fondaparinux 
on mortality and reinfarction in patients with acute ST-segment 
elevation mycardial infarction: the OASIS-6 randomized trial. JAMA. 
2006;295(13):1519–1530.
17.  Van de Werf F, Bax J, Betriu A, et al. Management of acute myocardial 
infarction in patients presenting with persistent ST-segment elevation: 
the Task Force on the Management of ST-Segment Elevation Acute 
Myocardial Infarction of the European Society of Cardiology. Eur 
Heart J. 2008;29(23):2909–2945.
18.  Bassand JP, Hamm CW, Ardissino D, et al. Guidelines for the diagnosis 
and treatment of non-ST-segment elevation acute coronary syndromes. 
The Task Force for the Diagnosis and Treatment of Non-ST-Segment 
Elevation Acute Coronary Syndromes of the European Society of 
Cardiology. Eur Heart J. 2007;28(13):1598–1660.
19.  Harrington RA, Becker RC, Cannon CP, et al. Antithrombotic therapy 
for non-ST-segment elevation acute coronary syndromes: American 
College of Chest Physicians Evidence-Based Clinical Practice Guide-
lines (8th Edition). Chest. 2008;133(6 Suppl):670S–707S.
20.  Schiele F, Meneveau N, Seronde MF, et al. Routine use of fondaparinux 
in acute coronary syndromes: a 2-year multicenter experience. 
Am Heart J. 2010;159(2):190–198.
21.  Mehta SR, Boden WE, Eikelboom JW, et al. Antithrombotic therapy 
with fondaparinux in relation to interventional management strategy in 
patients with ST- and non-ST-segment elevation acute coronary syn-
dromes: an individual patient-level combined analysis of the Fifth and 
Sixth Organization to Assess Strategies in Ischemic Syndromes (OASIS 
5 and 6) randomized trials. Circulation. 2008;118(20):2038–2046.
22.  Mehta SR, Granger CB, Eikelboom JW, et al. Efficacy and safety of 
fondaparinux versus enoxaparin in patients with acute coronary syn-
dromes undergoing percutaneous coronary intervention: results from 
the OASIS-5 trial. J Am Coll Cardiol. 2007;50(18):1742–1751.
23.  Goodman SG, Menon V , Cannon CP, Steg G, Ohman EM, Harrington RA. 
Acute ST-segment elevation myocardial infarction: American College 
of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th 
Edition). Chest. 2008;133(6 Suppl):708S–775S.
24.  Stief TW. Kallikrein activates prothrombin. Clin Appl Thromb Hemost. 
2008;14(1):97–98.
25.  Maegdefessel L, Buerke M, Schubert S, et al. Comparison of bivali-
rudin, enoxaparin, and unfractionated heparin in preventing cardiac 
catheter thrombosis. Results of an in-vitro study. Thromb Haemost. 
2008;100(4):693–698.
26.  Mehran R, Pocock SJ, Stone GW, et al. Associations of major bleeding 
and myocardial infarction with the incidence and timing of mortality in 
patients presenting with non-ST-elevation acute coronary syndromes: 
a risk model from the ACUITY trial. Eur Heart J. 2009;30(12): 
1457–1466.
27.  Cohen M, Mahaffey KW, Pieper K, et al. A subgroup analysis of the 
impact of prerandomization antithrombin therapy on outcomes in the 
SYNERGY trial: enoxaparin versus unfractionated heparin in non-
ST-segment elevation acute coronary syndromes. J Am Coll Cardiol. 
2006;48(7):1346–1354.
28.  Eikelboom J, Guyatt G, Hirsh J. Guidelines for anticoagulant use in 
acute coronary syndromes. Lancet. 2008;371(9624):1559–1561.
29.  Bassand JP, Hamm C. Guidelines for anticoagulant use in acute coronary 
syndromes. Lancet. 2008;372(9638):532–533; author reply 533–534.
30.  Kubisz P, Stasko J. Recombinant activated factor VII in patients at high 
risk of bleeding. Hematology. 2004;9(5–6):317–332.
31.  Haverkamp D, Hutten BA, Buller HR, Gallus AS, Lensing AW, 
Prins MH. The use of specific antidotes as a response to bleeding com-
plications during anticoagulant therapy for venous thromboembolism. 
J Thromb Haemost. 2003;1(1):69–73.
32.  Bijsterveld NR, Moons AH, Boekholdt SM, et al. Ability of recom-
binant factor VIIa to reverse the anticoagulant effect of the pentasac-
charide fondaparinux in healthy volunteers. Circulation. 2002;106(20): 
2550–2554.
33.  Kishimoto TK, Viswanathan K, Ganguly T, et al. Contaminated heparin 
associated with adverse clinical events and activation of the contact 
system. N Engl J Med. 2008;358(23):2457–2467.